CBAY
Cymabay Therapeutics
CBAY
CBAY
Delisted
CBAY was delisted on the 21st of March, 2024.
118 hedge funds and large institutions have $213M invested in Cymabay Therapeutics in 2022 Q1 according to their latest regulatory filings, with 22 funds opening new positions, 38 increasing their positions, 25 reducing their positions, and 17 closing their positions.
New
Increased
Maintained
Reduced
Closed
more call options, than puts
Call options by funds: $ | Put options by funds: $
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
more first-time investments, than exits
New positions opened: | Existing positions closed:
more funds holding
Funds holding: →
0% more funds holding in top 10
Funds holding in top 10: 6 → 6 (0)
1% less capital invested
Capital invested by funds: $216M → $213M (-$2.47M)
Holders
118
Holding in Top 10
6
Calls
$805K
Puts
$456K
Top Buyers
| 1 | +$991K | |
| 2 | +$939K | |
| 3 | +$872K | |
| 4 |
Renaissance Technologies
New York
|
+$758K |
| 5 |
HS
HighVista Strategies
Boston,
Massachusetts
|
+$645K |
Top Sellers
| 1 | -$2.3M | |
| 2 | -$1.01M | |
| 3 | -$663K | |
| 4 |
BNP Paribas Financial Markets
Paris,
France
|
-$357K |
| 5 |
NCM
Nantahala Capital Management
New Canaan,
Connecticut
|
-$330K |